Given the significant findings related to peri-transplant MRD positive or negative status and significant rates of relapse with FLT3+ AML, there has been significant interest in ongoing FLT-directed maintenance therapy after alloHCT while waiting to establish the donor GVL effect. Here, FLT3 is linked to acute myeloid leukemia.